Mechanism of Action
ARA-290 acts through the Tissue Protective Receptor (TPR), a heterodimer distinct from the classical EPO receptor.
Tissue Protective Receptor (TPR) Activation
The TPR is composed of the EPO receptor (EPOR) and CD131 (beta common receptor). ARA-290 binds this heterodimer with high affinity. Unlike the classical EPOR homodimer that drives erythropoiesis, the EPOR/CD131 heterodimer mediates cytoprotection in neurons, cardiac cells, and epithelial cells via anti-apoptotic (Akt/PI3K) and anti-inflammatory (reduced NF-kB) signaling.[1]Small Nerve Fiber Regeneration
ARA-290 promotes regrowth of small unmyelinated C-fiber and Adelta nerve fibers, the fibers responsible for pain, temperature sensation, and autonomic function that are specifically damaged in small fiber neuropathy, sarcoidosis, and diabetes. It increases intraepidermal nerve fiber density (IENFD) - a measurable biomarker used as a primary endpoint in Phase II trials.[2]Anti-inflammatory and Metabolic Protection
ARA-290 reduces macrophage-driven inflammation, protects pancreatic beta cells from cytokine-induced apoptosis, and improves insulin secretion in diabetic models. The combination of neuroprotection and metabolic protection makes it relevant for diabetic complications including both peripheral neuropathy and beta cell preservation.[3]Research Overview
Sarcoidosis Small Fiber Neuropathy
Phase II ClinicalPhase II trial in sarcoidosis-associated small fiber neuropathy (28 days, 4 mg SC daily): statistically significant improvement in corneal nerve fiber length, intraepidermal nerve fiber density, and autonomic function scores. Pain and fatigue scores also improved. These are the most direct human data showing ARA-290 promotes peripheral nerve regeneration.[2]
Diabetic Neuropathy and Beta Cell Protection
Phase II ClinicalARA-290 reduces pain scores in diabetic peripheral neuropathy in Phase II trials. Preclinical data shows preservation of pancreatic beta cell mass under cytokine stress, potentially relevant for both Type 1 and Type 2 diabetes neuropathic complications.[3]
Cardiac and Renal Ischemia Protection
Strong EvidenceARA-290 reduces infarct size and improves cardiac function in ischemia-reperfusion models. In renal ischemia models, it reduces acute kidney injury markers. The TPR is expressed in heart, kidney, and brain, making ARA-290 a broad-spectrum organ protector in ischemic conditions.[1]
Long COVID and Autonomic Dysfunction
EmergingPost-viral small fiber neuropathy is a documented feature of long COVID. ARA-290's Phase II sarcoidosis data (which also involves small fiber neuropathy) has generated interest in ARA-290 for long COVID autonomic symptoms. Research is in early stages.[2]
Calculate your ARA-290 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuropathy / nerve repair | 4 mg | Once daily × 28 days | Subcutaneous |
| Metabolic / beta cell support | 4 mg | Once daily | Subcutaneous |
| Cardiac / organ protection | 2–4 mg | Once daily | Subcutaneous |
No specific meal timing required. The Phase II trial protocol used 4 mg SC once daily for 28 consecutive days. Longer courses have been studied in chronic neuropathy. No fasting requirement.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
ARA-290 has a favorable Phase II safety profile.
No erythropoiesis: The key safety advantage, unlike EPO itself, ARA-290 does not raise hematocrit, does not cause hypertension, and does not increase thrombosis risk. This eliminates the primary safety concerns of EPO use.
FDA Orphan Drug designation: Granted for small fiber neuropathy, confirming the regulatory safety review pathway.
Well tolerated in Phase II: No dose-limiting toxicities identified in sarcoidosis neuropathy or diabetic neuropathy trials. Mild injection site reactions are the most common adverse event.
No FDA approval for treatment: Orphan Drug designation only; not yet approved for any therapeutic indication.
References
- [1]Brines M, Cerami A. "Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise." Kidney Int. 2006;70(2):246-250.
- [2]Brines M, et al. "ARA 290, a novel erythropoietin receptor ligand, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med. 2015;20:658-666.
- [3]van Velzen M, et al. "ARA 290, a non-erythropoietic EPO analogue, improves small fiber neuropathy in sarcoidosis." Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):188-196.